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The traffi   cking of lymphocytes from the blood 
into LNs and Peyer’s patches (PPs) is mediated 
by a cascade of adhesive interactions between 
circulating lymphocytes and the specialized 
  endothelial cells of high endothelial venules 
(HEVs) (1, 2). The adhesive interactions in-
clude rolling, fi  rm adhesion, and transendothe-
lial migration of lymphocytes across the HEV 
wall. In particular, lymphocyte rolling on the 
luminal surface of LN HEVs is governed by the 
interaction of lymphocyte L-selectin with spe-
cifi   c carbohydrate determinants presented on 
certain sialomucins expressed by LN HEVs (3).
L-selectin, a C-type lectin cell adhesion mole-
cule, specifi  cally recognizes a capping group of 
O-glycans known as 6-sulfo sialyl Lewis x in 
which the C-6 position of GlcNAc within 
the sialyl Lewis x is modifi  ed with sulfate (3). 
This structure can be presented at both core-2 
branches and extended core-1 structures of 
the O-glycans of HEV-associated sialomucins 
and shows L-selectin ligand activities in both 
  positions (4). Genetic studies in mice demon-
strated that certain patterns of fucosylation and 
carbohydrate sulfation are indeed required for 
L-selectin ligand functions in LN HEVs and 
that α-1,3-fucosyltransferase VII (FucTVII) (5) 
and L-selectin ligand sulfotransferase (LSST, also 
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Lymphocyte traffi  cking to lymph nodes (LNs) is initiated by the interaction between lym-
phocyte L-selectin and certain sialomucins, collectively termed peripheral node addressin 
(PNAd), carrying specifi  c carbohydrates expressed by LN high endothelial venules (HEVs). 
Here, we identifi  ed a novel HEV-associated sialomucin, nepmucin (mucin not expressed in 
Peyer’s patches [PPs]), that is expressed in LN HEVs but not detectable in PP HEVs at the 
protein level. Unlike conventional sialomucins, nepmucin contains a single V-type immuno-
globulin (Ig) domain and a mucin-like domain. Using materials affi  nity-purifi  ed from LN 
lysates with soluble L-selectin, we found that two higher molecular weight species of 
nepmucin (75 and 95 kD) were decorated with oligosaccharides that bind L-selectin as well 
as an HEV-specifi  c MECA-79 monoclonal antibody. Electron microscopic analysis showed 
that nepmucin accumulates in the extended luminal microvillus processes of LN HEVs. Upon 
appropriate glycosylation, nepmucin supported lymphocyte rolling via its mucin-like domain 
under physiological fl  ow conditions. Furthermore, unlike most other sialomucins, nepmucin 
bound lymphocytes via its Ig domain, apparently independently of lymphocyte function–
associated antigen 1 and very late antigen 4, and promoted shear-resistant lymphocyte 
binding in combination with intercellular adhesion molecule 1. Collectively, these results 
suggest that nepmucin may serve as a dual-functioning PNAd in LN HEVs, mediating both 
lymphocyte rolling and binding via different functional domains.
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known as HEC GlcNAc-6-sulfotransferase) (6, 7) are princi-
pal enzymes for the biosynthesis of 6-sulfo sialyl Lewis x in 
LN HEVs. This structure is recognized by an HEV-specifi  c 
mAb MECA-79 (8) that eff  ectively blocks lymphocyte roll-
ing on LN HEVs (9). The function-blocking activity of 
the MECA-79 mAb is explained by an overlap of its recognition 
epitope, an extended core-1 structure modifi  ed with GlcNAc-
6-sulfate, with the L-selectin recognition determinant (4). 
  Accordingly, the MECA-79 mAb and L-selectin recognize 
essentially the same glycoprotein complex in LN HEVs. 
These glycoproteins are collectively termed peripheral node 
addressin (PNAd).
Soluble L-selectin chimeric proteins and MECA-79 mAb 
have permitted the biochemical identifi  cation of the PNAds 
of mouse peripheral LNs and human tonsils as a series 
of   heterogeneous glycoproteins. Some of these have been 
cloned. These molecules include glycosylation-dependent 
cell   adhesion molecule 1 (GlyCAM-1) (10), CD34 (11, 12), 
endomucin (13, 14), and podocalyxin (15). Of these, CD34, 
endomucin, and podocalyxin are broadly distributed in vas-
cular endothelial cells in various organs, but L-selectin–reac-
tive glycoforms of these sialomucins are seen in LN HEVs 
only, demonstrating the importance of tissue-specifi  c post-
translational glycosylation events in LN HEVs for the genera-
tion of functional PNAd. Additional MECA-79–reactive 
glycoproteins of 75, 115, and 200 kD have been reported in 
mouse peripheral LNs (16, 17), but their molecular nature 
remains to be determined.
Although PNAd expressed by LN HEVs is critical for 
lymphocyte rolling on LN HEVs, the mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1) plays a vital role for both 
lymphocyte rolling on and adhesion to PP HEVs (17–19). 
MAdCAM-1 is a sialomucin-type cell adhesion molecule and 
carries a mucin-like domain and three (rodent) or two (human) 
Ig domains in its extracellular region (20, 21). The fi  rst 
Ig domain of MAdCAM-1 directly interacts with α4β7 inte-
grin (22), mediating both lymphocyte rolling on and fi  rm ad-
hesion to PP HEVs. In addition, MAdCAM-1 expressed in 
mesenteric LN HEVs is decorated with L-selectin–reactive 
sugar chains and supports L-selectin–dependent lymphocyte 
rolling (17). Thus, the mucosal addressin MAdCAM-1 may 
contribute to mucosal tissue–specifi  c lymphocyte traffi   cking 
by bridging the rolling and adhesion steps of lymphocytes in 
PP HEVs. On the other hand, no PNAd component that can 
mediate both the rolling and adhesion steps of lymphocytes 
in LN HEVs has yet been identifi  ed.
In this study, we identifi  ed a novel sialomucin, nepmucin 
(mucin not expressed in PPs), which is expressed in LN HEVs 
but not detectable in PP HEVs at the protein level. Nepmu-
cin carries a mucin-like domain and a single V-type Ig 
  domain. We show that certain isoforms of nepmucin (75 and 
95 kD) expressed in LN HEVs carry MECA-79 epitopes and 
bind L-selectin. Nepmucin that has been appropriately modi-
fi  ed with L-selectin–reactive sugar chains supports L-selec-
tin–dependent lymphocyte rolling through its mucin-like 
domain in vitro. In addition, nepmucin mediates lymphocyte 
binding through its Ig domain, and this binding appears to 
be independent of the LFA-1 or very late antigen 4 (VLA-4) 
adhesion pathway. Under physiological fl  ow conditions, in 
combination with intercellular adhesion molecule 1 (ICAM-1), 
nepmucin promotes chemokine-driven, shear-resistant lym-
phocyte binding. These observations suggest that the novel 
LN HEV-associated sialomucin nepmucin can serve as a 
dual-functioning PNAd component, regulating both the 
  rolling and adhesion steps of lymphocytes in LN HEVs.
RESULTS
Molecular cloning of cDNA encoding nepmucin
In a search for novel HEV-associated molecules by gene ex-
pression profi  ling (23, 24), we identifi  ed a cDNA fragment 
(GS11753) that is preferentially expressed in PNAd+ HEVs. 
By screening a cDNA library prepared from PNAd+ HEVs, 
we obtained several full-length cDNA clones encoding a type I 
Figure 1.  Amino acid sequence of mouse nepmucin and putative 
exon/intron structure. (A) The deduced amino acid sequence of 
  nepmucin. The putative signal sequence and the transmembrane region 
are represented by a broken underline and double underline, respectively. 
The putative Ig domain is underlined, and the cysteine residues partici-
pating in the Ig domain structure are circled. The tandem repeats in the 
mucin-like domain are boxed. (B) The exon/intron structure of mouse 
nepmucin gene and splicing isoforms. The genomic structure of nepmu-
cin was deduced by comparing the genomic sequence (AL591145) with 
the cDNA sequence of each nepmucin isoform (isoforms A, B, C, and D). 
All intron-exon boundaries follow the AG/GT rules. The nucleotide se-
quences of the nepmucin isoforms have been submitted under   accession 
numbers AB243063, AB243064, AB243065, and AB243066. TM, trans-
membrane domain.JEM VOL. 203, June 12, 2006  1605
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transmembrane protein of 415 amino acids (Fig. 1 A). The 
identifi  ed start codon is followed by a hydrophobic signal 
peptide, a single V-type Ig domain, and a mucin-like domain. 
The Ig domain shows substantial identity at the amino acid 
level to the corresponding region of human CMRF-35A (25) 
(40%), CMRF-35H (26) (38%), mouse DIgR (27) (40%), and 
mouse polymeric Ig receptor (28) (34% with V1 Ig domain). 
The mucin-like domain (43% serine, threonine, and proline 
residues) possesses tandem repeats of 26 amino acid residues, 
a pattern that is often observed in classical mucins (29), and is 
predicted to be heavily O-glycosylated. No N-linked glyco-
sylation site (N-X-S/T) was observed. The cytoplasmic tail 
contains a single potential protein kinase C phosphorylation 
site (S/T-X-R/K) and a negatively charged amino acid stretch 
at the COOH terminus. We assigned the name nepmucin 
(mucin not expressed in PPs) to this molecule because of its 
structural characteristics and selective expression in LN HEVs 
as described below. Comparison of the isolated cDNA 
  sequences with the corresponding genomic sequence 
(AL591145) showed that the nepmucin gene is comprised of 
eight exons that undergo alternative splicing to generate four 
isoforms (isoforms A–D, Fig. 1 B). The mouse nepmucin 
gene is located on chromosome 11 and one nepmucin iso-
form (isoform D) has been reported as CLM-9 without 
known functions (30). The diff  erentially spliced exons (exons 
3 and 4a) encode the mucin-like domain, and thus each nep-
mucin isoform has a mucin-like domain of a diff  erent size.
Cellular and tissue distribution of nepmucin
We next examined nepmucin mRNA expression in various 
types of cells by RT-PCR. Nepmucin mRNA could be de-
tected in the PNAd+ HEVs and MAdCAM-1+ HEVs, but 
not in any of the cultured endothelial cell lines examined 
(Fig. 2 A). Nepmucin mRNA expression was also observed 
in some myeloid lineage cell lines (WEHI3B, MH-S, and 
P388D1) and CD11c+ DCs, but not in a mast cell line (P815) 
or purifi  ed T and B lymphocytes. The expression of nepmu-
cin in DCs was detected in the CD11b+CD8− subset but not 
the CD11b−CD8+ subset (unpublished data). These results 
indicate that nepmucin is preferentially expressed in certain 
types of endothelial and myeloid lineage cells. As shown in 
Fig. 2 B, RT-PCR analysis using a primer pair that can de-
tect all the nepmucin isoforms revealed that splicing isoforms 
A, B, C, and D (highest expression level) are all expressed in 
MAdCAM-1+ HEVs at the mRNA level.
To analyze nepmucin expression at the protein level, we 
performed Western blotting analysis of various tissue samples 
using an anti-nepmucin mAb (ZAQ2). We found that nep-
mucin is expressed as multiple bands with approximate mo-
lecular sizes of 95, 75, 50, and 35 kD in the stromal cell 
fraction of peripheral LNs and whole peripheral LN lysates 
(Fig. 2 C). A similar set of bands, of 80, 70, 50, and 35 kD, 
was detected in various tissues, including mesenteric LNs, 
spleen, thymus, lung, heart (highest expression), and kidney. 
The diff  erence in molecular weight of the antigenic compo-
nents between peripheral LNs (95 and 75 kD) and other 
  tissues (80 and 70 kD) was due to the degree of glycosylation, 
as described below. Nepmucin was almost undetectable in 
the small intestine, brain, and PPs. When the O-glycan chains 
of nepmucin were removed enzymatically, the apparent mo-
lecular sizes of the nepmucin isoforms decreased markedly 
(Fig. 2 D, arrows) to 52, 46, 40, and 32 kD (Fig. 2 D, arrow-
heads), which are in accord with the theoretical molecular 
sizes of nepmucin isoforms A, B, C, and D, respectively (45, 
40, 37, and 32 kD). These observations indicate that nepmu-
cin is expressed in a variety of tissues at the protein level and 
is heavily modifi  ed with O-linked carbohydrates. The four 
nepmucin components detected by Western blotting ap-
peared to represent the nepmucin isoforms A, B, C, and D.
Nepmucin is expressed in HEVs in peripheral 
and mesenteric LNs, but not in those of PPs
We next performed a histochemical analysis of nepmucin ex-
pression in lymphoid and nonlymphoid tissues. As shown in 
Fig. 3 (A–F), two-color immunofl  uorescence staining with 
an anti-nepmucin mAb and HEV-specifi  c  mAbs  revealed 
Figure 2.  Cell and tissue expression of nepmucin. (A) Nepmucin 
mRNA expression analyzed by RT-PCR. Left: HEV cDNA libraries (PNAd+ 
HEVs and MAdCAM-1+ HEVs), endothelial cell lines (KOP2.16, SVEC4-10, 
bEND3, and F2), monocyte/macrophage cell lines (WEHI3B, MH-S, and 
P388D1), and a mast cell line (P815) were analyzed. Right: Freshly isolated 
MAdCAM-1+ HEV cells, T cells, B cells, and DCs were analyzed. The PCR 
primers were designed to detect all the nepmucin isoforms as a single 
band. (B) Expression of nepmucin splicing isoforms in freshly isolated 
MAdCAM-1+ HEVs. A primer pair designed to detect nepmucin isoforms 
with different product sizes was used. (C) Tissue distribution of nepmucin. 
The expression of nepmucin was analyzed by Western blotting using the 
anti-nepmucin mAb ZAQ2, which recognized all four nepmucin variants 
(arrows). Control rat IgG2a did not give any specifi  c signals (unpublished 
data). (D) Enzymatic O-deglycosylation of nepmucin. Lysates from mouse 
heart were subjected to immunoprecipitation with ZAQ2 and mock-
treated (lane 1) or treated with O-glycanase (lane 2). The proteins were 
analyzed with the anti-nepmucin mAb, ZAQ3. The arrows and arrowheads 
indicate the four kinds of antigenic components.1606  NEPMUCIN MEDIATES LYMPHOCYTE ROLLING AND BINDING | Umemoto et al.
that nepmucin was expressed in the PNAd+ HEVs and 
MAdCAM-1+ HEVs of LNs. A small fraction of high endothe-
lial  cells appeared to express nepmucin at only low levels 
(Fig. 3, A–F). Nepmucin was also expressed in small non–HEV-
type blood vessels in LNs (unpublished data). Interestingly, 
nepmucin was not detectable in the blood vessels in PPs, in-
cluding the MAdCAM-1+ HEVs, at the protein level (Fig. 3, 
G–I, and Fig. S1, which is available at http://www.jem.org/
cgi/content/full/jem.20052543/DC1). No nepmucin signal 
was observed in PP HEVs by in situ hybridization analysis 
(Fig. S1 A), whereas low-grade mRNA expression was de-
tected in purifi  ed PP HEVs (Fig. S1, B and C). In the spleen, 
nepmucin was observed in the CD31+ cells in the trabecula 
and marginal sinus, but not in the CD31+ cells of the central 
arteriole (Fig. 3, J and K). Nepmucin was also found on the 
splenic marginal sinus-lining cells known to express MAd-
CAM-1 (Fig. 3 L) (31). In the heart, nepmucin expression 
was detected in the intramuscular capillaries but not the arteries 
(Fig. 3, M–O). These fi  ndings demonstrate that nepmucin is 
selectively expressed in endothelial cells of certain small blood 
vessels, including the HEVs in peripheral LNs and mesenteric 
LNs, but not in PPs at the protein level.
Nepmucin in peripheral LN HEVs binds L-selectin 
and displays the MECA-79 epitope
Because nepmucin has a mucin-like domain and is heavily 
decorated with O-glycans, we hypothesized that HEV-de-
rived nepmucin binds L-selectin and displays the MECA-79 
epitope. To test this hypothesis, L-selectin–binding materials 
purifi   ed from peripheral LNs were subjected to Western 
blotting with the anti-nepmucin mAb. As shown in Fig. 4 A 
(right, arrowheads), the two major L-selectin–binding mo-
lecular species (95 and 75 kD) were detected among the four 
nepmucin isoforms in total peripheral LN lysates (left, arrows). 
Figure 3.  Distribution pattern of nepmucin in mouse tissues. Two-
color immunostaining of peripheral LNs with anti-nepmucin (A), anti-PNAd (B), 
and the merged image (C); two-color immunostaining of mes  enteric LNs 
with anti-nepmucin (D), anti-MAdCAM-1 (E), and the merged image (F). 
A–F shows that nepmucin was expressed in HEVs in peripheral LNs and 
mesenteric LNs. Two-color staining of PPs with anti-nepmucin (G) and 
anti–MAdCAM-1 (H) revealed that nepmucin was undetectable in PP 
HEVs. Double staining with anti-nepmucin and anti-CD31 showed that 
nepmucin was also undetectable in non–HEV-type vessels in PPs (I). Two 
color staining of spleen with anti-nepmucin (J–L) and anti-CD31 (J and K) 
or anti–MAdCAM-1 (L). The expression of nepmucin was found in the 
marginal sinus and trabecula (J), but not in central arteries (K). Nepmucin 
was also detected in the MAdCAM-1+ sinus-lining cells (L). Two-color 
staining of heart with anti-nepmucin (M), anti-CD31 (N), and the merged 
image (O) showed that nepmucin was selectively expressed in the intra-
muscular capillaries but not the arteries. Scale bar, 50 μm (C, F, K, L, and O) 
and 100 μm (H, I, and J). Negative control rat IgG for anti-nepmucin did 
not bind tissue sections (unpublished data).JEM VOL. 203, June 12, 2006  1607
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The addition of EDTA abrogated the precipitation of nep-
mucin by soluble L-selectin, indicating that the interaction of 
L-selectin with nepmucin is calcium dependent. When nep-
mucin was affi   nity purifi  ed from the peripheral LN lysates 
and subjected to Western blotting with the MECA-79 mAb, 
at least three nepmucin species (95, 75, and 50 kD) were rec-
ognized by the MECA-79 mAb (Fig. 4 B, middle, arrow-
heads). PNAd components with similar molecular sizes (95, 
75, and 50 kD) were detected by the MECA-79 mAb in the 
total peripheral LN lysates (Fig. 4 B, left, asterisks). As shown 
in Fig. 4 C, the higher molecular weight species of nepmucin 
(95 and 75 kD) that were reprecipitated from L-selectin–
binding materials were recognized by the MECA-79 mAb. 
Upon treatment with O-sialoglycoprotein endopeptidase 
(OSGE), which specifi  cally cleaves the peptide backbone of 
sialomucins (32), the L-selectin–binding materials were no 
longer precipitated by the anti-nepmucin mAb (Fig. 4 D, 
left), and upon treatment with sialydase, the 95- and 75-kD 
nepmucin isoforms showed increased electrophoretic mobili-
ties (Fig. 4 D, right). Collectively, these observations indicate 
that at least two of the higher molecular weight species of 
nepmucin that are expressed in peripheral LN HEVs (95 and 
75 kD) are decorated with sialylated O–linked sugar chains 
carrying the MECA-79 epitope and bind L-selectin.
Nepmucin is expressed on the luminal surface 
of LN HEV cells
We next performed immunoelectron microscopic analysis to 
examine the ultrastructural localization of nepmucin in LN 
HEVs. As shown in Fig. 5 A, an anti-nepmucin mAb (ZAQ5) 
bound to the luminal surface of LN HEVs. In particular, the 
immunoreactivity was mainly in the extended luminal 
Figure 4.  Interaction of nepmucin expressed in peripheral LN HEVs 
with L-selectin and MECA-79 mAb. (A) Reactivity of L-selectin–binding 
materials with anti-nepmucin mAb. Total cell lysates of peripheral LNs 
were immunoblotted with the anti-nepmucin mAb ZAQ2 (left). Lysates of 
peripheral LNs were precipitated with LEC/IgG chimeric protein or control 
human IgG, with or without EDTA, and analyzed by Western blotting with 
ZAQ2 (right). The two major antigenic components are indicated by arrow-
heads. (B) Reactivity of the nepmucin in peripheral LN HEVs with the 
MECA-79 mAb. Total cell lysates of peripheral LNs were immunoblotted 
with the MECA-79 mAb (left). Lysates of mouse peripheral LNs were 
  immunoprecipitated with anti-nepmucin or control rat IgG, and immuno-
blotted with MECA-79 (middle) or the anti-nepmucin mAb ZAQ2 (right). 
MECA-79 recognized three nepmucin species (arrows) among the four 
isoforms (white arrowheads). In A and B, isotype-matched controls to 
anti-nepmucin and MECA-79 gave no specifi  c signals (unpublished data). 
(C) Reprecipitation of nepmucin from L-selectin–binding materials. 
L-selectin–binding materials were reprecipitated with ZAQ2 or rat IgG 
and analyzed by Western blotting using MECA-79 (left) or ZAQ2 (right). 
(D) Sensitivity of nepmucin to OSGE or sialydase. L-selectin–binding ma-
terials treated with OSGE were subjected to immunoprecipitation with the 
anti-nepmucin mAb, ZAQ2 (left). Alternatively, L-selectin–binding materi-
als were reprecipitated with ZAQ2 and then treated with sialydase (right). 
The precipitates were analyzed with MECA-79. Arrowheads indicate the 
higher molecular weight species of nepmucin.
Figure 5.  Ultrastructural localization of nepmucin in peripheral LN 
HEVs. (A) Anti-nepmucin mAb ZAQ5 bound to the vascular luminal sur-
face of LN HEVs. (B) A higher magnifi  cation view of the area shown within 
the square in A shows that nepmucin was frequently concentrated on the 
extended luminal microvillous process near the intracellular junction. In 
addition, nepmucin appeared to be localized in the site of internalized 
plasma membrane (arrow) and in the tubular- or spherical-shaped endo-
somal vesicles (arrowheads) below the endothelial cell surface. (C) Nep-
mucin was detectable on the lateral surface of LN HEVs. A multivesicular 
body (asterisk) was positive for nepmucin. (D) A higher magnifi  cation view 
of the lateral junction area shown within the square in C showed the 
anti-nepmucin mAb located on the lateral membranes of the high endo-
thelial cells, where they formed loose connections (arrowheads). Ly, 
lymphocyte. Bars, 1 μm (A and C) and 0.5 μm (B and D).1608  NEPMUCIN MEDIATES LYMPHOCYTE ROLLING AND BINDING | Umemoto et al.
  microvillous processes near the intracellular junctions (Fig. 5 B) 
where L-selectin–binding substrates reportedly are concentrated 
(33). As shown in Fig. 5 (C and D), the anti-nepmucin 
mAb also labeled the lateral surface of HEVs, especially where 
the endothelial cells form loose connections or are interdigi-
tated (Fig. 5 D), whereas in the basal region, there was little 
anti-nepmucin mAb immunoreactivity. In addition, the anti-
nepmucin mAb appeared to react with the site of internalized 
plasma membrane (Fig. 5 B, arrow), tubular- or spherical-
shaped endosomal vesicles (Fig. 5 B, arrowheads) with the 
size of 100 to 200 nm, as well as the multivesicular bodies 
(Fig. 5 C, asterisk) (34). These observations indicate that nep-
mucin is localized to the luminal surface as well as the endo-
cytic compartment of LN HEVs, an expression pattern that 
is compatible with the idea that nepmucin can serve as an 
HEV-associated cell surface ligand of L-selectin.
Nepmucin can mediate L-selectin–dependent cell rolling 
through its mucin-like domain
We next investigated whether nepmucin, when appropri-
ately glycosylated, can mediate L-selectin–dependent lym-
phocyte rolling under physiological shear stress. For this 
purpose, we fi  rst produced a series of nepmucin-Fc chimeric 
proteins in A5-Core1 cells, which express a specifi  c set 
of carbohydrate-modifying enzymes (core2 β-1,6-N-acetyl-
glucosaminyltransferase [C2GnT] [35], core1 extension-
β1,3-N-acetylglucosaminyltransferase [C1GnT] [4], FucTVII 
[5], and LSST [6]), which together generate L-selectin–reac-
tive oligosaccharides. As shown in Fig. 6 A, the nepmucin 
full-length (FL)-Fc and ∆Ig-Fc chimeras as well as GlyCAM-1-
Fc bound the MECA-79 mAb, whereas the ∆mucin-Fc chi-
mera did not, indicating that the chimeric proteins bearing an 
intact mucin domain were all appropriately glycosylated.
We next examined whether nepmucin supports lympho-
cyte rolling under fl  ow conditions using these chimeric 
  proteins. The recombinant proteins were immobilized on the 
inside wall of glass capillary tubes, and lymphocytes were in-
fused into the capillaries at a shear stress of 0.8 dyne/cm2 (Fig. 
6 B). We found that lymphocytes rolled on the surface when 
it was coated with nepmucin FL-Fc, ∆Ig-Fc, or GlyCAM-
1-Fc, but not with ∆mucin-Fc, indicating that upon appropri-
ate glycosylation, nepmucin can mediate lymphocyte rolling 
through its mucin-like domain. As shown in Fig. 6 C, the 
velocity class with the highest number of rolling cells was 
90–100 μm/s (average rolling velocity: 93.6 ± 30.1 μm/s, 
n = 70) on FL-Fc, whereas it was 110–120 μm/s (average 
rolling velocity: 106.5 ± 21.5 μm/s, n = 70) on GlyCAM-1-
Fc, indicating that nepmucin can mediate lymphocyte rolling 
at least as eff  ectively as GlyCAM-1 in vitro. Pretreatment of 
the lymphocytes with an anti–L-selectin mAb or EDTA (Fig. 
6 D), or treatment of the immobilized nepmucin FL-Fc with 
the MECA-79 mAb, OSGE, or sialydase (Fig. 6 E), com-
pletely abrogated the rolling, indicating that the rolling was 
mediated by lymphocyte L-selectin and the MECA-79 epit-
ope-bearing oligosaccharides on nepmucin. Collectively, 
these results demonstrate that upon appropriate glycosylation, 
nepmucin can serve as a functional scaff  old for L-selectin–
  reactive carbohydrates to mediate L-selectin–dependent lym-
phocyte rolling under physiological fl  ow conditions.
Nepmucin can bind lymphocytes through its Ig domain 
under static conditions
Nepmucin carries an Ig domain that is linked in tandem to 
the mucin-like domain in its extracellular region. This struc-
tural feature led us to speculate that nepmucin mediates lym-
phocyte binding through its Ig domain, as is the case with 
Figure 6.  L-selectin–dependent cell rolling mediated by nepmucin-
Fc produced in CHO cells expressing C2GnT, C1GnT, FucTVII, and 
LSST. (A) Preparation of chimeric proteins decorated with MECA-79+ 
sugar chains. Nepmucin FL-Fc, ∆Ig-Fc, ∆mucin-Fc, and GlyCAM-1-Fc 
were produced in the A5-Core1 cells and analyzed with MECA-79 mAb. 
(B) Lymphocyte rolling on immobilized chimeras under fl  ow. The inside 
wall of capillary tubes was coated with one of the chimeric proteins or 
human IgG (20 μg/ml). Jurkat cells (2 × 106 cells/ml) were infused into 
the capillary tubes (0.8 dyne/cm2), and the rolling cell number was deter-
mined. (C) Lymphocyte rolling velocity at a shear stress of 0.8 dyne/cm2. 
The histograms display the rolling cell number observed at the indicated 
rolling velocity. (D) Inhibition of lymphocyte rolling by EDTA or anti–
L-selectin mAb. Lymphocytes were pretreated with EDTA, anti–L-selectin 
(DREG-56), or control human IgG1 before the infusion. (E) Inhibition of 
lymphocyte rolling by treating immobilized nepmucin with MECA-79, 
OSGE, or sialydase. Glass capillaries were fi  rst coated with Fc chimeras 
and treated as indicated before the rolling assay.JEM VOL. 203, June 12, 2006  1609
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MAdCAM-1 (19). To test this hypothesis, we performed 
a lymphocyte-binding assay under static conditions. As shown 
in Fig. 7 A, immobilized nepmucin FL-Fc or ∆mucin-Fc 
produced in the A5-Core1 cells showed readily detectable 
binding of unstimulated lymphocytes, whereas nepmucin 
∆Ig-Fc, GlyCAM-1-Fc, ICAM-1-Fc, or human IgG1 did 
not. When the lymphocytes were stimulated with PMA, 
nepmucin FL-Fc and ∆mucin-Fc, but not ∆Ig-Fc, showed 
increased lymphocyte binding, the extent of which was com-
parable to that observed with ICAM-1-Fc. The lymphocyte 
binding to nepmucin was apparently independent of L-selec-
tin–reactive sugar chains because nepmucin chimeras pre-
pared in Cos-7 cells, which do not modify proteins with 
these sugars, gave essentially the same results as described 
above (unpublished data). When the immobilized nepmucin 
∆mucin-Fc was treated with a panel of anti-nepmucin mAbs 
(ZAQ1, ZAQ2, ZAQ3, and ZAQ4) that recognize the Ig 
domain of nepmucin, ZAQ3 and ZAQ4 abolished the lym-
phocyte binding, whereas ZAQ1, ZAQ2, and control rat 
IgG did not. Collectively, these results indicate that nepmu-
cin can bind lymphocytes through its Ig domain and that one 
or more epitopes in nepmucin’s Ig domain are critical for 
their binding.
We next examined whether the LFA-1 and VLA-4 adhe-
sion pathways are involved in the lymphocyte binding to 
  nepmucin. To this end, lymphocytes were pretreated with 
neutralizing mAbs to LFA-1 or VLA-4, either alone or in 
combination, and tested for their binding to nepmucin in the 
presence or absence of PMA. As shown in Fig. 7 C, the prein-
cubation of lymphocytes with anti–LFA-1 in the presence of 
PMA abrogated lymphocyte binding to ICAM-1 but not to 
nepmucin. Similarly, pretreatment with anti–VLA-4 in the pres-
ence of PMA abrogated lymphocyte binding to MAdCAM-1 
but not to nepmucin. It is of note that lymphocytes bound to 
nepmucin moderately well in the absence of PMA, and this 
binding was not aff  ected by anti–LFA-1 or anti–VLA-4. These 
results indicate that lymphocytes bind to nepmucin indepen-
dently of the LFA-1 and VLA-4 adhesion pathways.
To further address possible involvement of integrins in 
lymphocyte binding to nepmucin, we tested divalent cation 
requirements by using EDTA and Mn2+. As shown in Fig. 7 D, 
EDTA totally abolished PMA-induced LFA-1–dependent 
lymphocyte binding to ICAM-1 but only partially to nep-
mucin. Mn2+ signifi  cantly increased lymphocyte binding to 
ICAM-1 but failed to aff  ect that to nepmucin. Shear resis-
tance is a hallmark of integrin-mediated lymphocyte binding 
Figure 7.  Lymphocyte binding to nepmucin via its Ig domain. 
(A) Binding of lymphocytes to nepmucin-Fc chimeras. Nepmucin FL-Fc, 
∆Ig-Fc, ∆mucin-Fc, GlyCAM-1-Fc, ICAM-1-Fc, and human IgG1 Fc were immo-
bilized on glass slides and incubated with splenocytes in the presence or 
absence of PMA. The number of cells bound per unit area was determined 
microscopically, and the mean ± SD from three independent areas is 
given. The data are representative of at least three independent experi-
ments. (B) Effects of anti-nepmucin mAb pretreatment on lymphocyte 
adhesion. Coated proteins were incubated with a panel of anti-nepmucin 
mAbs that specifi  cally recognize the Ig domain (ZAQ1, ZAQ2, ZAQ3, and 
ZAQ4) or with the control rat IgG. The number of cells bound under PMA 
stimulation is shown. (C) The effects of anti–LFA-1 and/or anti–VLA-4 on 
nepmucin-mediated lymphocyte binding. Lymphocytes pretreated with 
anti–LFA-1 and/or anti–VLA-4 or rat IgG were incubated with or without 
PMA. (D) Effects of EDTA and Mn2+ on nepmucin-mediated lymphocyte 
binding. Splenocytes were preincubated in the presence or absence of 
EDTA on immobilized proteins and stimulated with or without PMA or 
MnCl2. (E) Detachment of lymphocytes bound to nepmucin under fl  ow. Fc 
chimeras were immobilized on the inner surface of glass capillaries with or 
without CCL21. Lymphocytes were injected into the capillaries and allowed 
to accumulate on the substrate at a shear stress of 0.125 dyne/cm2. The 
shear stress was then increased in twofold increments every 20 s. The lym-
phocytes that remained adherent at each shear-stress level were counted 
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upon chemokine stimulation. As observed in Fig. 7 E, upon 
lymphocyte stimulation with CCL21, lymphocytes bound to 
ICAM-1 via integrin LFA-1 in a shear-resistant manner. In 
sharp contrast, even in the presence of CCL21, lymphocytes 
bound to nepmucin detached when shear stress was increased 
(>2.0 dyne/cm2; Fig. 7 E). Collectively, these observations 
suggest that lymphocyte binding to nepmucin is independent 
of lymphocyte integrins.
Nepmucin promotes lymphocyte adhesion in combination 
with ICAM-1 under fl  ow conditions
We next investigated whether nepmucin cooperates with 
ICAM-1 to mediate chemokine-driven shear-resistant lym-
phocyte adhesion under physiological fl   ow conditions. To 
this end, the nepmucin FL-Fc was immobilized either alone 
or in combination with ICAM-1-Fc on the inner surface of 
capillary tubes in the presence or absence of CCL21, and lym-
phocytes were infused into the capillary at a shear stress of 1.1 
dyne/cm2. GlyCAM-1-Fc and human IgG were used as con-
trols. When immobilized alone, nepmucin FL-Fc and Gly-
CAM-1-Fc mediated lymphocyte rolling at comparable levels 
(Fig. 8 A). As shown in Fig. 8 B, in the absence of CCL21, 
nepmucin FL-Fc but not GlyCAM-1-Fc coimmobilized with 
either the control IgG or ICAM-1-Fc showed a small but 
measurable amount of lymphocyte adhesion (P < 0.005). 
When CCL21 was coimmobilized as well, shear-resistant 
  adhesion of rolling lymphocytes was observed in capillaries 
coated with nepmucin FL-Fc or GlyCAM-1-Fc in combina-
tion with ICAM-1-Fc. The number of lymphocytes bound 
to the capillaries coated with nepmucin FL-Fc plus ICAM-1-
Fc (81.7 ± 7.0 cells/fi  eld) was about twofold that observed in 
the capillaries coated with GlyCAM-1-Fc plus ICAM-1-Fc 
(40.7 ± 4.7 cells/fi  eld). The increased lymphocyte binding 
was not observed with nepmucin that lacks the Ig domain 
(Fig. 8 C). Collectively, these observations indicate that in 
combination with ICAM-1, nepmucin can enhance the che-
mokine-driven shear-resistant adhesion of rolling lympho-
cytes via its Ig domain under physiological fl  ow conditions.
DISCUSSION
In this study, we identifi  ed a novel HEV-associated sialomucin, 
nepmucin, which is selectively expressed in LN HEVs but not 
detectable in PP HEVs at the protein level. At least the two 
higher molecular weight isoforms of peripheral LN HEV-de-
rived nepmucin (75 and 95 kD) are decorated with L-selectin–
reactive oligosaccharides bearing the MECA-79 epitope and 
bind L-selectin. Upon appropriate glycosylation, nepmucin can 
support L-selectin–dependent lymphocyte rolling under physi-
ological fl  ow conditions in vitro. Furthermore, nepmucin me-
diates lymphocyte binding via its Ig domain, apparently 
independently of lymphocyte LFA-1 and VLA-4, and, in com-
bination with ICAM-1, can enhance chemokine-driven shear-
resistant lymphocyte binding. Collectively, these observations 
indicate that nepmucin can serve as a dual-functioning sialomu-
cin, mediating both lymphocyte rolling and binding through its 
mucin-like domain and Ig domain, respectively.
Previously identifi  ed PNAd-forming sialomucins, such as 
CD34, podocalyxin, and endomucin, are widely expressed in 
the vascular endothelial cells of a variety of tissues. In con-
trast, nepmucin was preferentially expressed in the endothe-
lial cells of small blood vessels in various tissues, including 
capillaries of the heart and spleen, and in LN HEVs, but was 
not detectable in PP HEVs. Currently, the transcriptional 
regulation of the nepmucin gene remains unknown.
Alternative splicing of the nepmucin gene generates four 
splice variants in which the mucin-like domain is of diff  erent 
lengths (isoforms A–D). All are expressed in the LN HEVs. 
Of these, the two with the higher molecular weight (75 and 
95 kD) were decorated with L-selectin–reactive sugar chains 
Figure 8.  Enhancement of lymphocyte adhesion to an ICAM-1–
coated substrate by nepmucin under fl  ow conditions. (A) Lymphocyte 
rolling on Fc chimeras under fl  ow conditions. Nepmucin FL-Fc, GlyCAM-
1-Fc, ICAM-1-Fc, or human IgG was immobilized on the inside wall of 
capillary tubes that had been coated with goat anti–human IgG. Lympho-
cytes were infused into the capillary tubes (1.1 dyne/cm2), and the num-
ber of cells that rolled in 0.64 mm2 per min was counted. (B) Lymphocyte 
adhesion on nepmucin FL-Fc coimmobilized with ICAM-1-Fc under fl  ow 
conditions. Fc chimeric proteins were coimmobilized on the inside of cap-
illary tubes with or without CCL21 as indicated. Lymphocytes were in-
fused into the capillary, and the number of bound cells in 0.29 mm2 was 
determined. Data represent the mean ± SD from three independent 
  areas. *, P < 0.005. (C) Lymphocyte adhesion to nepmucin’s Ig domain 
under fl  ow. Fc chimeras and CCL21 were immobilized on the inside of 
capillaries as in B. Lymphocytes were injected into the capillaries, and 
bound cells were counted.JEM VOL. 203, June 12, 2006  1611
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carrying the MECA-79 epitope, which binds L-selectin. 
PNAd components with an apparent molecular size of  90 
kD have been reported to be comprised of multiple sialomu-
cins (36), including CD34 (11, 12) and endomucin (13, 14). 
The presence of a PNAd component of 75 kD has also been 
reported in the mouse LN (17). Thus, the 95- and 75-kD 
isoforms of nepmucin described here might have been in-
cluded in the previously detected PNAd components.
The in vitro rolling experiments clearly showed that 
  recombinant nepmucin, which was produced in A5-Core1 
cells expressing a specifi  c set of carbohydrate-modifying en-
zymes (C2GnT, C1GnT, FucTVII, and LSST), supported 
lymphocyte rolling under physiological fl  ow conditions that 
was abolished by the anti–L-selectin or MECA-79 mAb, in-
dicating that appropriately glycosylated nepmucin can medi-
ate L-selectin–dependent lymphocyte rolling. The nepmucin’s 
mucin-like domain was necessary for this activity because 
nepmucin mutants lacking the mucin-like domain but not 
the Ig domain failed to support lymphocyte rolling. The lym-
phocyte rolling behavior observed on the nepmucin chimera 
was quantitatively and qualitatively comparable to that ob-
served on the GlyCAM-1 chimeric protein. Nepmucin was 
distributed to the microvillous structure on the luminal sur-
face of LN HEVs where L-selectin ligands are localized (33). 
These observations fully support the hypothesis that nepmu-
cin serves as a functional ligand for L-selectin and mediates 
lymphocyte rolling when appropriately glycosylated by a spe-
cifi  c set of carbohydrate-modifying enzymes in LN HEVs.
Multiple sialomucins contribute to the generation of 
functional PNAd in LN HEVs. It remains unclear, however, 
whether diff  erent PNAd components expressed in LN HEVs 
play either distinct or redundant roles in lymphocyte rolling. 
The absence of overt defects in lymphocyte traffi   cking across 
the HEV walls in mice defi  cient in CD34 (36), GlyCAM-1, 
or both (37) supports the hypothesis that the HEV-associated 
sialomucins cooperate functionally to play redundant roles so 
that the loss of one or more PNAd member can be compen-
sated for by other members. We are now attempting to inac-
tivate the nepmucin gene in vivo so that we can directly 
assess nepmucin’s role in HEVs.
The traffi   cking of lymphocytes to the LNs and PPs is ini-
tiated by lymphocyte rolling on HEVs, which is followed by 
fi  rm adhesion of lymphocytes to the luminal surface of HEVs. 
Although the mucosal addressin MAdCAM-1 in PP HEVs 
has been shown to participate in both lymphocyte rolling on 
(18) and adhesion to (19) PP HEVs, the PNAd components 
in LN HEVs have been thought to play a role only in the 
initial lymphocyte rolling process, but not in the subsequent 
lymphocyte adhesion step. In this regard, we note that unlike 
most conventional sialomucins expressed in LN HEVs, nep-
mucin carries an NH2-terminal Ig domain and supports lym-
phocyte binding via the Ig domain in the apparent absence of 
the lymphocyte integrins LFA-1 and VLA-4 under static 
conditions. Furthermore, in combination with ICAM-1, 
nepmucin enhanced CCL21-driven shear-resistant lympho-
cyte adhesion, suggesting that nepmucin contributes to the 
step of the adhesion of lymphocytes to HEVs. Nepmucin 
may decelerate the velocity of rolling lymphocytes through 
its Ig domain and thereby successfully bridge the initial roll-
ing and subsequent adhesion steps of lymphocytes in the 
HEVs, as has been suggested for MAdCAM-1 (38). The 
identifi  cation of putative counterreceptor(s) for nepmucin’s 
Ig domain should help elucidate this issue.
The Ig domain of nepmucin has substantial homology to 
that of the mouse polymeric Ig receptor (28) and CMRF-35 
family members (human CMRF-35A [25], CMRF-35H 
[26], and mouse DIgR [27]). Recently, Chung et al. (30) 
found that a gene cluster of the mouse CMRF-35–like mole-
cule (CLM) family (CLM-1-9) is located on chromosome 11. 
They changed the name of mouse DIgR to CLM-4 and sug-
gested that mouse CLM-5 and CLM-8 are the human homo-
logues of CMRF-35A and CMRF-35H, respectively. Based 
on the sequence identity, nepmucin appears to correspond to 
CLM-9. Because CLM-9 lies apart from the genes encoding 
the other CLM members, which are all clustered within 
240 kb on chromosome 11, nepmucin/CLM-9 may be a distant 
relative of the other CLM family members. The gene encod-
ing the human ortholog of nepmucin was found in the 
  GenBank database (accession no. BC025395). Like mouse 
nepmucin, the human counterpart bears a potential protein 
kinase C phosphorylation site and a cluster of negative charges 
in its cytoplasmic region, suggesting that nepmucin and its 
human ortholog participate in intracellular signaling.
In conclusion, our study demonstrates that a novel LN 
HEV-associated sialomucin, nepmucin, mediates lymphocyte 
rolling and binding through its mucin-like domain and Ig 
domain, respectively. Further investigation of the physiologi-
cal signifi  cance of nepmucin in vivo is now warranted, which 
should lead to a more precise understanding of the molecular 
mechanisms underlying homeostatic lymphocyte traffi   cking 
across the HEVs.
MATERIALS AND METHODS
Animals. C57BL/6 mice were purchased from CLEA Japan and Japan SLC. 
SD rats were purchased from CLEA Japan. The experimental protocol was 
approved by the Ethics Review Committee for Animal Experimentation of 
Osaka University Medical School.
Reagents. Biotinylated mAbs to mouse B220 (RA3-6B2), CD3 (145-
2C11), CD11c (HL3), and CD31 (MEC13.3) were obtained from BD Bio-
sciences. The hybridomas producing anti-PNAd mAb (MECA-79) and 
anti–MAdCAM-1 mAb (MECA-367) were provided by E.C. Butcher 
(Stanford University School of Medicine, Stanford, CA) (8, 39). The mouse 
L-selectin-IgG chimeric protein (LEC/IgG) was produced in COS-7 cells as 
described previously (40).
Full-length cDNA library of PNAd+ HEVs. PNAd+ HEV cells were 
purifi   ed as described previously (23), and total RNA was isolated with 
TRIzol reagent (Invitrogen). A cDNA library was prepared using a SMART 
cDNA library construction kit (CLONTECH Laboratories, Inc.). The orig-
inal PNAd+ HEV cDNA library contained 6.5 × 106 recombinants/ml 
  before amplifi  cation.
Isolation of nepmucin cDNA. By comparing the expression profi  les 
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identifi  ed a 3′-cDNA fragment of nepmucin (GS11753). A corresponding 
cDNA sequence was found in the GenBank EST database (AK009375). To 
isolate full-length nepmucin cDNA, a cDNA fragment was amplifi  ed by 
PCR using a primer pair (sense, 5′-C  A  A  G  A  G  C  T  C  T  C  G  A  T  G  A  C  C  G  T  G  -3′; 
antisense, 5′-T  C  T  C  C  T  C  C  A  G  C  A  A  T  T  G  A  T  G  C  A  G  -3′) alkaline phos-
phatase labeled by AlkPhos Direct (GE Healthcare) and used for screening 
the PNAd+ HEV cDNA library by plaque hybridization. Duplicate fi  lter lifts 
containing 5.0 × 104 plaques were hybridized at 55°C overnight, and 30 in-
dependent clones were obtained and sequenced. Comparison with the ge-
nomic sequence (AL591145) showed these clones represented four splicing 
isoforms (isoforms A–D; see Fig. 1 B).
RT-PCR. Total RNA was extracted using TRIzol reagent (Invitrogen) 
from purifi  ed PNAd+ HEVs, MAdCAM-1+ HEVs, endothelial cell lines 
(KOP2.16, SVEC4-10, bEND3, and F2), monocyte/macrophage cell lines 
(WEHI3B, MH-S, and P388D1), a mast cell line (P815), freshly isolated 
CD3+ T cells, B220+ B cells, and CD11c+ DCs from peripheral LNs puri-
fi  ed by autoMACS (Miltenyi Biotec). Single-strand cDNA was synthesized 
using the Ready-To-Go kit (GE Healthcare) and used in RT-PCR with 
Ex-Taq DNA polymerase (Takara Bio). PCR was performed at 95°C for 
5 min, 32 cycles at 94°C for 30 s, at 62°C for 30 s, at 72°C for 1 min, and a 
fi  nal extension at 72°C for 5 min using the following primer pairs: β-actin: 
sense, 5′-A  T  G  G  A  T  G  A  C  G  A  T  A  T  C  G  C  T  -3′, antisense, 5′-A  T  G  A  G  G  T  A  G-
T  C  T  G  T  C  A  G  G  T  -3′; and nepmucin: sense, 5′-A  G  A  C  T  C  G  A  C  G  A  T  A  G  A  C-
C  T  T  G  C  A  G  -3′, antisense, 5′-T  C  T  C  C  T  C  C  A  G  C  A  A  T  T  G  A  T  G  C  A  G  -3′, all 
the nepmucin isoforms detected as a single band; sense, 5′-C  A  A  G  A  G  C  T  C-
T  C  G  A  T  G  A  C  C  G  T  G  -3′, antisense, 5′-C  A  C  A  G  A  G  A  T  G  A  A  C  T  C  A  G  A  G  A-
A  G  G  -3′, the nepmucin splicing isoforms detected as distinct bands with 
diff  erent product sizes.
Generation of nepmucin-human Ig chimeras. cDNA fragments en-
coding the extracellular domain of full-length nepmucin (isoform A, amino 
acids 19–284), nepmucin lacking the mucin-like domain (isoform D, amino 
acids 19–126 connected to 255–284), and nepmucin lacking the Ig domain 
(amino acids 126–284) were amplifi  ed by PCR and inserted into the CD5 
leader hIgG vector (provided by B. Seed, Harvard Medical School, Boston, 
MA). COS-7 cells were transfected with the plasmids by a DEAE-dextran 
method, and the chimeric proteins (termed FL-Fc, ∆mucin-Fc, and ∆Ig-Fc, 
respectively) were purifi  ed from the culture supernatant with Hitrap protein 
A (GE Healthcare).
Generation of mAbs against nepmucin. The protein A–purifi  ed chime-
ric protein (FL-Fc) was injected into the footpads of female SD rats, and the 
popliteal LN cells were fused with P3-X63.Ag8.653 mouse myeloma cells. 
Hybridomas producing anti-nepmucin mAb (ZAQ1, ZAQ2, ZAQ3, 
ZAQ4, and ZAQ5 [all IgG2a]) were cloned by limiting dilution. These 
ZAQ antibodies recognized the Ig domain of nepmucin, as determined by 
ELISA using nepmucin-Fc chimeras.
Western blotting and immunoprecipitation. Mouse tissue lysates were 
prepared as described previously (14). For Western blot analyses, samples 
from each tissue (30 μg/lane) were separated by SDS-PAGE under nonre-
ducing conditions and transferred to PVDF fi  lters. After being blocked with 
PBS containing 3% BSA, the fi  lter was incubated with an anti-nepmucin 
mAb (ZAQ2) or control rat IgG2a (Santa Cruz Biotechnology, Inc.), fol-
lowed by horseradish peroxidase–conjugated goat anti–rat IgG (American 
Qualex). For immunoprecipitation, the peripheral LN lysate was precleared 
with protein G–sepharose 4B (GE Healthcare), and CaCl2 was added to 
  restore the calcium ion concentration (2 mM). The anti-nepmucin mAb 
ZAQ2 or LEC/IgG premixed with protein G–sepharose 4B was added to 
the lysate, and the solution was incubated at 4°C overnight. The precipitated 
materials were subjected to SDS-PAGE and immunoblotting using a combi-
nation of MECA-79 mAb and horseradish peroxidase anti–rat IgM (Jackson 
ImmunoResearch Laboratories) or biotinylated anti-nepmucin (ZAQ2) and 
ABC reagent (Vector Laboratories). For reimmunoprecipitation experiments, 
LN lysates were fi  rst precipitated with LEC/IgG, eluted with 5 mM EDTA, 
and subjected to reprecipitation with anti-nepmucin (ZAQ2) or control rat 
IgG. The precipitated proteins were analyzed by Western blotting using the 
MECA-79 mAb. Biotinylated rat IgG2a (anti-CD8α [53–6.7]; eBioscience) 
and rat IgM (Chemicon International) were used as isotype-matched   controls 
for ZAQ2 and MECA-79, respectively.
Enzyme treatment of nepmucin. For O-deglycosylation, nepmucin 
  affi   nity purifi  ed from heart lysates was treated with a mixture of 50 mU/ml 
α-1,3/4-L-fucosidase (Takara Bio), 0.16 U/ml sialydase from Clostridium 
perfi  ngen (Prozyme), 0.1 U/ml β-1,4-galactosidase (Prozyme), 2 U/ml 
β-N-acetylglucosaminidase (Prozyme), and 40 mU/ml endo-α-N-acetyl-
galactosaminidase (O-glycanase; Glyko) in 50 mM sodium phosphate, pH 
7.0, at 37°C for 40 h. The samples were subjected to SDS-PAGE and 
Western blotting using biotinylated anti-nepmucin (ZAQ3) and ABC 
  reagent. For OSGE digestion, L-selectin–binding materials from peri-
pheral LNs were treated with 0.3 mg/ml OSGE (Cedarlane) in PBS at 
37°C overnight and subjected to reprecipitation with an anti-nepmucin 
(ZAQ2). For sialydase digestion, the L-selectin–binding materials were 
reprecipitated with an anti-nepmucin mAb, ZAQ2, followed by incuba-
tion with 0.2 U/ml sialydase in 50 mM sodium phosphate, pH 5.5, at 
37°C overnight. These samples were analyzed by Western blotting using 
the MECA-79 mAb.
Immunohistochemistry. Frozen sections were fi  xed in acetone, blocked 
with Block Ace (Dainippon Seiyaku), and incubated with an anti-nepmucin 
mAb (ZAQ1 or ZAQ2) or control rat IgG (Cappel), followed by FITC-
conjugated goat anti–rat IgG (Cappel). After blocking with rat IgG, the sec-
tions were further incubated with a combination of biotinylated mAbs 
(MECA-79, MECA-367, or MEC13.3 [anti-CD31]) and Alexa Fluor 594–
conjugated streptavidin (Invitrogen).
Immunoelectron microscopy. Immunoelectron microscopy was per-
formed as described previously (41). In brief, mice were fi  xed by transcardial 
perfusion of cold periodate-lysine-paraformaldehyde solution, and the pe-
ripheral LNs were removed. After postfi  xation with the same fi  xative, the 
samples were embedded in OCT compound (Sakura) and snap frozen. 10-μm-
thick frozen sections were incubated with the culture supernatant of an 
anti-nepmucin mAb, ZAQ5, followed by ABC reagent. The sections were 
then fi  xed with 1% glutaraldehyde and 2% osmium tetroxide solutions, de-
hydrated in graded ethanol, and embedded in epoxy resin. Ultrathin sections 
were stained with lead citrate and examined in a transmission electron micro-
scope (JEM-1230; JEOL).
Generation of recombinant nepmucin-Fc carrying MECA-79 
  epitopes. CHO cells stably expressing human C2GnT, human FucTVII (42), 
and human LSST (6) (A5 cells) (14) were transfected with pcDNA6 (Invit-
rogen) containing a cDNA encoding human C1GnT (4). The resulting line 
was called A5-Core1 cells. The A5-Core1 cells were transiently transfected 
with expression plasmids containing cDNA encoding FL-Fc, ∆mucin-Fc, 
∆Ig-Fc, or GlyCAM-1-Fc (6) using the Escort V lipofection reagent (Sigma-
Aldrich). Chimeric proteins were purifi  ed from the culture supernatant 
  using a protein A column.
Rolling assay. The inside wall of 0.69-mm-diameter capillary tubes (Drum-
mond Scientifi  c) was coated with one of the recombinant proteins (20 μg/
ml) in Tris-buff  ered saline, pH 9.0, at 4°C overnight and blocked with FCS 
for 5 min at room temperature. Jurkat cells (2 × 106 cells/ml) were infused 
into the capillary at a shear stress of 0.8 dyne/cm2 at room temperature. The 
fl  ow rate was controlled by a Harvard syringe pump (PHD 2000; Instech 
Laboratories). 3 min after the start of the infusion, cell images were recorded 
with a cell-viewing system (SRM-100; Nikon) and video recorder (BR-
S600; Victor). For the inhibition studies, the cells were pretreated with 
5 μg/ml anti–L-selectin (DREG-56; BD Biosciences) or 10 mM EDTA. In 
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MECA-79, 50 mU/ml sialydase in 50 mM sodium acetate, pH 5.2, contain-
ing 0.1% BSA, or 0.16 mg/ml of OSGE in PBS, or left untreated.
Static adhesion assay. 4-mm-diameter multiwell glass slides were coated 
with 10 μg/ml recombinant nepmucin-Fc, GlyCAM-1-Fc, rat ICAM-1-
Fc (provided by Y. Iigo, Daiichi Pharmaceutical Co., Tokyo, Japan), rat 
MAdCAM-1-Fc (43), or recombinant human IgG1 Fc (R&D Systems) at 
4°C overnight and blocked with FCS. 2 × 105 plastic nonadherent spleen 
cells were added and allowed to settle for 5 min. PMA (50 ng/ml fi  nal con-
centration) or control buff  er (RPMI 1640 containing 0.1% BSA) was added, 
and the cells were incubated for an additional 5 min at 37°C. After the 
  unbound cells were washed off  , the bound cells were counted. For blocking 
experiments, immobilized chimeric proteins were preincubated with anti-
nepmucin mAbs or rat IgG for 45 min, or splenocytes were preincubated 
with anti-CD11a (KBA) (44) or anti-CD49d (PS/2) (45) (20 μg/ml) for 
10 min. In some experiments, splenocytes were incubated on the chimeric 
protein–coated slide glass in the presence or absence of 10 mM EDTA, 
  followed by an additional incubation for 5 min with or without 50 ng/ml 
PMA or 2 mM MnCl2.
Detachment assay. The inside wall of glass capillaries was coated with 
nepmucin FL-Fc or ICAM-1-Fc (10 μg/ml each) at 4°C overnight and 
blocked with FCS for 5 min. The downstream half of each tube was addi-
tionally coated with 2 μM mouse CCL21 (R&D Systems). Plastic nonad-
herent spleen cells (106 cells/ml) were injected into the capillary tubes at 
0.125 dyne/cm2 for 5 min at 37°C. The fl  ow was then increased in twofold 
increments every 20 s. The number of the cells that remained bound in an 
0.18-mm2 microscope fi  eld was determined by counting at each interval.
Flow adhesion assay. The inner surface of glass capillary tubes was coated 
with 10 μg/ml goat anti–human IgG (Cappel), followed by nepmucin-Fc or 
GlyCAM-1-Fc in combination with ICAM-1-Fc or human IgG (20 μg/ml 
each) for 2 h at room temperature, and blocked with FCS for 5 min. Addi-
tionally, the downstream half of each tube was coated with 2 μM mouse 
CCL21 for 5 min. Mouse splenocytes were prepared as described previously 
(46), and the cells (3 × 106 cells/ml) were infused into the capillaries at a 
shear stress of 1.1 dyne/cm2 at 37°C. After a 1–2-min stabilization period, the 
cell behavior was monitored as described above. The number of cells bound 
(i.e., that remained stationary for at least 20 s) per randomly selected 0.29-mm2 
microscope fi  eld was determined 9 min after the start of monitoring.
Statistical analysis. A Student’s t test was applied to compare the statistical 
diff  erence within two groups.
Online supplemental material. Fig. S1 shows results obtained in in situ 
hybridization and real-time PCR analyses for nepmucin expression in HEVs 
of mesenteric LNs and PPs. Fig. S1 and supplemental Materials and methods 
are available at http://www.jem.org/cgi/content/full/jem.20052543/DC1.
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